Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00471978 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

DNA Analysis of Blood and Tissue From Patients With Lung Cancer

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 11 months later Sep 2026 → Sep 2028
See other at-risk trials from Massachusetts General Hospital

Record History

  1. Primary and study completion pushed from Sep 2026 to Sep 2028 Enrollment changed: None → 15000 · Study description expanded, about 6 words · Eligibility criteria expanded, about 5 words Show 3 more changesShow less
    • Enrollment changed: None → 15000
    • Study description expanded, about 6 words
    • Eligibility criteria expanded, about 5 words
  2. Primary completion date: Jun 2023 to Sep 2026 Enrollment target: 6800 to not stated · Completion date: Sep 2023 to Sep 2026 · Study description expanded, about 8 wordsv20 Show 3 more changesShow less
    • Enrollment target: 6800 to not stated
    • Completion date: Sep 2023 to Sep 2026
    • Study description expanded, about 8 words

    See this version in full on ClinicalTrials.gov ↗

  3. Primary completion date: Jun 2022 to Jun 2023 Completion date: Sep 2022 to Sep 2023 · Eligibility criteria shortened, about 17 words · Study description expanded, about 6 wordsv19 Show 3 more changesShow less
    • Completion date: Sep 2022 to Sep 2023
    • Eligibility criteria shortened, about 17 words
    • Study description expanded, about 6 words

    See this version in full on ClinicalTrials.gov ↗

  4. Re-verified, no change to tracked fieldsv18
  5. Primary completion date: Jun 2017 to Jun 2022 Completion date: Sep 2017 to Sep 2022v17 Show 1 more changeShow less
    • Completion date: Sep 2017 to Sep 2022
Show 15 earlier versionsHide 15 earlier versions
  1. Primary completion date: Jun 2011 to Jun 2017 Completion date: Sep 2017 · Eligibility criteria expanded, about 16 wordsv16 Show 2 more changesShow less
    • Completion date: Sep 2017
    • Eligibility criteria expanded, about 16 words

    See this version in full on ClinicalTrials.gov ↗

  2. Interventions: laboratory biomarker analysis (Other), polymerase chain reaction (Genetic), polymorphism analysis (Genetic) to diagnostic laboratory biomarker analysis (Other), polymerase chain reaction (Genetic), polymorphism analysis (Genetic)v15
  3. Primary completion date: Apr 2009 to Jun 2011v14
  4. Re-verified, no change to tracked fieldsv13
  5. Interventions: laboratory biomarker analysis (Procedure), polymerase chain reaction (Procedure), polymorphism analysis (Procedure) to laboratory biomarker analysis (Other), polymerase chain reaction (Genetic), polymorphism analysis (Genetic)v12
  6. 2 versions Re-verified since Jul 23, 2008, no change to tracked fieldsv10-v11
  7. Interventions: diagnostic procedure (Procedure), laboratory biomarker analysis (Procedure), molecular genetic technique (Procedure), polymerase chain… to laboratory biomarker analysis (Procedure), polymerase chain reaction (Procedure), polymorphism analysis (Procedure)v9
  8. Re-verified, no change to tracked fieldsv8
  9. Primary completion date: Apr 2009v7
  10. Start date: Sep 2005v6
  11. Interventions: diagnostic test (Procedure), genetic analysis (Procedure), laboratory biomarker analysis (Procedure), polymerase chain reaction… to diagnostic procedure (Procedure), laboratory biomarker analysis (Procedure), molecular genetic technique (Procedure), polymerase chain…v5
  12. Interventions: biological markers (Procedure), diagnostic test (Procedure), genetic analysis (Procedure), polymerase chain reaction (Procedure)… to diagnostic test (Procedure), genetic analysis (Procedure), laboratory biomarker analysis (Procedure), polymerase chain reaction…v4
  13. Study Status, Study Design, Outcome Measuresv3
  14. Study sites revised (2)v2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This clinical trial is analyzing the DNA in blood and tissue samples from patients with lung cancer.
Trial Details
NCT Number NCT00471978
Lead Sponsor Massachusetts General Hospital
Collaborators: National Cancer Institute (NCI)
Conditions Lung Cancer
Enrollment 15,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov